A Phase II Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2015
At a glance
- Drugs MK 2206 (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 13 Sep 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.